# A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

> **NCT02410213** · PHASE2 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Iron Deficiency Anemia (IDA)

## Interventions

- **DRUG:** Ferric Carboxymaltose (FCM)

## Key facts

- **NCT ID:** NCT02410213
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-19
- **Primary completion:** 2017-01-22
- **Final completion:** 2017-06-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410213, "A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02410213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*